Boster Immunoleader

antibody

Anti-CCN1 Antibody

PB9549

100 ug/vial

240 USD

polyclonal

rabbit

human, rat

Anti-CCN1 Antibody

PB9549

Polyclonal

Rabbit IgG polyclonal antibody for Protein CYR61(CYR61) detection. Tested with WB in Human;Rat.

240 USD

Rabbit IgG

100 ug/vial

Lyophilized

No cross reactivity with other proteins.

Reacts with: human, rat

WB

Concentration: 0.1-0.5μg/ml; Tested Species: Human, Rat

Tested Species: In-house tested species with positive results. Other applications have not been tested. Optimal dilutions should be determined by end users.

E.coli-derived human CCN1 recombinant protein (Position: K54-D381). Human CCN1 shares 91.8% and 92.1% amino acid (aa) sequence identity with mouse and rat CCN1, respectively.

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg NaN3.

Immunogen affinity purified.

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

At -20˚C for one year. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for a longer time. Avoid repeated freezing and thawing.

Boster provides a series of assays reacted with primary antibodies. Antibody can be supported by chemiluminescence kit EK1002 in WB.

Cysteine-rich angiogenic inducer 61 (CYR61) or CCN family member 1 (CCN1), is a matricellular protein that in humans is encoded by the CYR61 gene. CYR61 is a secreted, extracellular matrix (ECM)-associated signaling protein of the CCN family (CCN intercellular signaling protein). And it is capable of regulating a broad range of cellular activities, including cell adhesion, migration, proliferation, differentiation, apoptosis, and senescence through interaction with cell surface integrin receptors and heparan sulfate proteoglycans. During embryonic development, CYR61 is critical for cardiac septal morphogenesis, blood vessel formation in placenta, and vascular integrity. In adulthood CYR61 plays important roles in inflammation and tissue repair, and is associated with diseases related to chronic inflammation, including rheumatoid arthritis, atherosclerosis, diabetes-related nephropathy and retinopathy, and many different forms of cancers.

1. Lau LF (October 2011). "CCN1/CYR61: the very model of a modern matricellular protein". Cell. Mol. Life Sci. 68 (19): 3149–63. 2. Jay P, Berge-Lefranc JL, Marsollier C, Mejean C, Taviaux S, Berta P (May 1997). "The human growth factor-inducible immediate early gene, CYR61, maps to chromosome 1p". Oncogene 14 (14): 1753–7. 3. Jun JI, Lau LF (December 2011). "Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets". Nature Reviews Drug Discovery 10 (12): 945–63.

CYR61

Protein CYR61

cysteine-rich, angiogenic inducer, 61

3CH61 antibody CCN 1 antibody CCN family member 1 antibody CCN1 antibody CCN1 antibody CYR 61 antibody Cyr61 antibody CYR61 protein antibody CYR61 protein precursor antibody CYR61 protein precursor antibody CYR61_HUMAN antibody Cysteine rich angiogenic inducer 61 antibody Cysteine rich angiogenic inducer 61 antibody Cysteine rich angiogenic inducer 61 antibody Cysteine rich heparin binding protein 61 antibody Cysteine-rich angiogenic inducer 61 antibody GIG 1 antibody GIG1 antibody GIG1 protein antibody GIG1 protein antibody IBP-10 antibody IGF-binding protein 10 antibody Igfbp 10 antibody IGFBP-10 antibody IGFBP10 antibody IGFBP10 antibody Insulin like growth factor binding protein 10 antibody Insulin like growth factor binding protein 10 antibody Insulin like growth factor binding protein 10 antibody Insulin-like growth factor-binding protein 10 antibody Protein CYR61 antibody Protein GIG1 antibody

O00622